ON THE SOCIAL TRAITS OF LUMINOUS BLUE VARIABLES von Humphreys, Roberta M., Weis, Kerstin, Davidson, Kris, Gordon, Michael S.

Volltext

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients von Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen

Volltext

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study von McDermott, David F, Sosman, Jeffrey A, Sznol, Mario, Massard, Christophe, Gordon, Michael S, Hamid, Omid, Powderly, John D, Infante, Jeffrey R, Fassò, Marcella, Wang, Yan V, Zou, Wei, Hegde, Priti S, Fine, Gregg D, Powles, Thomas

Volltext

Exploring the Mass-loss Histories of the Red Supergiants von Humphreys, Roberta M., Helmel, Greta, Jones, Terry J., Gordon, Michael S.

Volltext

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial von Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD

Volltext

Submillimeter-wavelength Polarimetry of IRC+10216 von Andersson, B-G., Karoly, Janik, Bastien, Pierre, Soam, Archana, Coudé, Simon, Tahani, Mehrnoosh, Gordon, Michael S., Fox-Middleton, Sydney

Volltext

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer von HERBST, Roy S, ECKHARDT, S. Gail, ASHKENAZI, Avi, JUBB, Adrian M, MENDELSON, David S, KURZROCK, Razelle, EBBINGHAUS, Scot, O'DWYER, Peter J, GORDON, Michael S, NOVOTNY, William, GOLDWASSER, Meredith A, TOHNYA, Tanyifor M, LUM, Bert L

Volltext

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study von Horn, Leora, Gettinger, Scott N., Gordon, Michael S., Herbst, Roy S., Gandhi, Leena, Felip, Enriqueta, Sequist, Lecia V., Spigel, David R., Antonia, Scott J., Balmanoukian, Ani, Cassier, Philippe A., Liu, Bo, Kowanetz, Marcin, O'Hear, Carol, Fassò, Marcella, Grossman, William, Sandler, Alan, Soria, Jean-Charles

Volltext

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advan... von Gordon, Michael S, Sweeney, Christopher S, Mendelson, David S, Eckhardt, S Gail, Anderson, Abraham, Beaupre, Darrin M, Branstetter, Daniel, Burgess, Teresa L, Coxon, Angela, Deng, Hongjie, Kaplan-Lefko, Paula, Leitch, Ian M, Oliner, Kelly S, Yan, Lucy, Zhu, Min, Gore, Lia

Volltext

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer von AGUS, David B, GORDON, Michael S, KELSEY, Stephen M, FYFE, Gwen, TAYLOR, Charles, NATALE, Ronald B, KARLAN, Beth, MENDELSON, David S, PRESS, Michael F, ALLISON, David E, SLIWKOWSKI, Mark X, LIEBERMAN, Gracie

Volltext

Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer von Jameson, Gayle S., Hosein, Peter J., Pierce, Erin, Kamgar, Mandana, Gordon, Michael S., Snyder, Courtney, Roe, Denise J., Wertheim, Betsy C., Davey, Marina, Barrett, Michael T., Von Hoff, Daniel D., Borazanci, Erkut

Volltext

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status von GORDON, Michael S, MATEI, Daniela, COHN, David E, ROMAN, Lynda, DERYNCK, Mika K, NG, Kimmie, LYONS, Benjamin, ALLISON, David E, EBERHARD, David A, PHAM, Think Q, DERE, Randall C, KARLAN, Beth Y, AGHAJANIAN, Carol, MATULONIS, Ursula A, BREWER, Molly, FLEMING, Gini F, HAINSWORTH, John D, GARCIA, Agustin A, PEGRAM, Mark D, SCHILDER, Russell J

Volltext

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial von Guigay, Joël, Lee, Keun-Wook, Patel, Manish R, Daste, Amaury, Wong, Deborah J, Goel, Sanjay, Gordon, Michael S, Gutierrez, Martin, Balmanoukian, Ani, Le Tourneau, Christophe, Mita, Alain, Vansteene, Damien, Keilholz, Ulrich, Schöffski, Patrick, Grote, Hans Juergen, Zhou, Dongli, Bajars, Marcis, Penel, Nicolas

Volltext

Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology von RIZZO, J. Douglas, LICHTIN, Alan E, MILLER, Carole B, RARICK, Mark U, REGAN, David H, BROWMAN, George P, GORDON, Michael S, WOOLF, Steven H, SEIDENFELD, Jerome, BENNETT, Charles L, CELLA, David, DJULBEGOVIC, Benjamin, GOODE, Matthew J, JAKUBOWSKI, Ann A, LEE, Stephanie J

Volltext

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody von Farwell, Michael D, Gamache, Raymond F, Babazada, Hasan, Hellmann, Matthew D, Harding, James J, Korn, Ron, Mascioni, Alessandro, Le, William, Wilson, Ian, Gordon, Michael S, Wu, Anna M, Ulaner, Gary A, Wolchok, Jedd D, Postow, Michael A, Pandit-Taskar, Neeta

Volltext

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer von Massard, Christophe, Gordon, Michael S, Sharma, Sunil, Rafii, Saeed, Wainberg, Zev A, Luke, Jason, Curiel, Tyler J, Colon-Otero, Gerardo, Hamid, Omid, Sanborn, Rachel E, O'Donnell, Peter H, Drakaki, Alexandra, Tan, Winston, Kurland, John F, Rebelatto, Marlon C, Jin, Xiaoping, Blake-Haskins, John A, Gupta, Ashok, Segal, Neil H

Volltext

Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovaria... von CHAMBERS, Setsuko K, CLOUSER, Mary C, GORDON, Alan N, NAGLE, Raymond B, WRIGHT, Heather M, COHEN, Janice L, ALBERTS, David S, BAKER, Amanda F, ROE, Denise J, HAIYAN CUI, BREWER, Molly A, HATCH, Kenneth D, GORDON, Michael S, JANICEK, Mike F, ISAACS, Jeffrey D

Volltext

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial von CLARK, Joseph I, ATKINS, Michael B, WEISS, Geoffrey R, REDMAN, Bruce G, TRETTER, Christopher P. G, MCDERMOTT, David, SMITH, John W, GORDON, Michael S, MARGOLIN, Kim A, URBA, Walter J, CREECH, Steven, FIGLIN, Robert A, DUTCHER, Janice P, FLAHERTY, Larry, SOSMAN, Jeffrey A, LOGAN, Theodore F, WHITE, Richard

Volltext

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and... von Choueiri, Toni K, Larkin, James, Oya, Mototsugu, Thistlethwaite, Fiona, Martignoni, Marcella, Nathan, Paul, Powles, Thomas, McDermott, David, Robbins, Paul B, Chism, David D, Cho, Daniel, Atkins, Michael B, Gordon, Michael S, Gupta, Sumati, Uemura, Hirotsugu, Tomita, Yoshihiko, Compagnoni, Anna, Fowst, Camilla, di Pietro, Alessandra, Rini, Brian I

Volltext

Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine von Blue, Thomas R, Gordon, Michael S, Schwartz, Robert P, Couvillion, Kathryn, Vocci, Frank J, Fitzgerald, Terrence T, O'Grady, Kevin E

Volltext